JCI Insight (Aug 2022)

Ligand-independent integrin β1 signaling supports lung adenocarcinoma development

  • Scott M. Haake,
  • Erin J. Plosa,
  • Jonathan A. Kropski,
  • Lindsay A. Venton,
  • Anupama Reddy,
  • Fabian Bock,
  • Betty T. Chang,
  • Allen J. Luna,
  • Kateryna Nabukhotna,
  • Zhi-Qi Xu,
  • Rebecca A. Prather,
  • Sharon Lee,
  • Harikrishna Tanjore,
  • Vasiliy V. Polosukhin,
  • Olga M. Viquez,
  • Angela Jones,
  • Wentian Luo,
  • Matthew H. Wilson,
  • W. Kimryn Rathmell,
  • Pierre P. Massion,
  • Ambra Pozzi,
  • Timothy S. Blackwell,
  • Roy Zent

Journal volume & issue
Vol. 7, no. 15

Abstract

Read online

Integrins — the principal extracellular matrix (ECM) receptors of the cell — promote cell adhesion, migration, and proliferation, which are key events for cancer growth and metastasis. To date, most integrin-targeted cancer therapeutics have disrupted integrin-ECM interactions, which are viewed as critical for integrin functions. However, such agents have failed to improve cancer patient outcomes. We show that the highly expressed integrin β1 subunit is required for lung adenocarcinoma development in a carcinogen-induced mouse model. Likewise, human lung adenocarcinoma cell lines with integrin β1 deletion failed to form colonies in soft agar and tumors in mice. Mechanistically, we demonstrate that these effects do not require integrin β1–mediated adhesion to ECM but are dependent on integrin β1 cytoplasmic tail-mediated activation of focal adhesion kinase (FAK). These studies support a critical role for integrin β1 in lung tumorigenesis that is mediated through constitutive, ECM binding–independent signaling involving the cytoplasmic tail.

Keywords